Seeking Alpha
Recommended for you:
-
dasdasdasdadas
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Are you looking to expand your portfolio with biotechnology stocks? If so, this list may be of interest to you.

We wanted to find biotechnology stocks with bullish indicators. To do so, we narrowed down our universe of biotech stocks to those meeting all of the following criteria:

- Net insider buying over the last 6 months

- Undervalued relative to Earnings per share (NYSEARCA:EPS) target price

- Market cap over $300M

We were left with the 5 names detailed below.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Insiders and analysts seem to think these stocks have some value to price in. Do you agree? Use the list below as a starting-off point for your own analysis.

1. Complete Genomics, Inc. (NASDAQ:GNOM): Biotechnology Industry. Market cap of $498.22M. Current price at $15.37 vs. target price $18.38 (implies a potential upside of 19.58%). Net insider purchases over the past 6 months at 1.65M representing 21.29% of the company's 7.75M share float.

2. QLT Inc. (NASDAQ:QLTI): Biotechnology Industry. Market cap of $352.78M. Current price at $6.78 vs. target price $10 (implies a potential upside of 47.49%). Net insider purchases over the past 6 months at 258,318, representing 0.79% of the company's 32.58M share float. It's been a rough couple of days for the stock, losing 8.07% over the last week.

3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Biotechnology Industry. Market cap of $5.16B. Current price at $56.72 vs. target price $65.45 (implies a potential upside of 15.39%). Net insider purchases over the past 6 months at 675,375, representing 0.96% of the company's 70.34M share float. The stock has gained 113.63% over the last year.

4. Theravance Inc. (NASDAQ:THRX): Biotechnology Industry. Market cap of $1.91B. Current price at $21.29 vs. target price $27.8 (implies a potential upside of 30.58%). Net insider purchases over the past 6 months at 5.19M, representing 9.92% of the company's 52.32M share float. The stock is a short squeeze candidate, with a short float at 8.61% (equivalent to 14.49 days of average volume). The stock has performed poorly over the last month, losing 10.57%.

5. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Biotechnology Industry. Market cap of $398.04M. Current price at $5.97 vs. target price $9.17 (implies a potential upside of 53.6%). Net insider purchases over the past 6 months at 433,240, representing 8.21% of the company's 52.80M share float. The stock is a short squeeze candidate, with a short float at 10.21% (equivalent to 8.5 days of average volume). The stock has performed poorly over the last month, losing 11.24%.

*Insider data sourced from Yahoo! Finance, other relevant data sourced from Finviz.

Source: 5 Biotech Stocks With Insider Buying and Undervalued by Analysts' EPS